Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;10(4):526-529.
doi: 10.21037/hbsn-21-215.

Liver metastases "siphon" off immunotherapy response

Nina Cortese  1 , Federica Marchesi  1   2
Affiliations
Editorial

Liver metastases "siphon" off immunotherapy response

Nina Cortese et al. Hepatobiliary Surg Nutr. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/hbsn-21-215). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Macrophage-mediated T cell killing hampers systemic response to IT in liver metastases. (A) Liver metastases result in systemic T cell loss due to contact-dependent elimination of antigen-specific T cells by immunosuppressive monocyte-derived hepatic macrophages. (B) Applicability to the therapeutic setting of gastrointestinal cancers poorly responding to single-agent checkpoint inhibitors. Combination of liver radiation and IT results in response, following rewiring of the liver microenvironment. Created with BioRender.com. IT, immunotherapy.
See this image and copyright information in PMC

Comment on

  • Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
    Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Yu J, et al. Nat Med. 2021 Jan;27(1):152-164. doi: 10.1038/s41591-020-1131-x. Epub 2021 Jan 4. Nat Med. 2021. PMID: 33398162 Free PMC article.

References

    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. 10.1126/science.aar4060 - DOI - PMC - PubMed
    1. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 2017;168:707-23. 10.1016/j.cell.2017.01.017 - DOI - PMC - PubMed
    1. Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med 2021;27:152-64. 10.1038/s41591-020-1131-x - DOI - PMC - PubMed
    1. Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med 2021;27:34-44. 10.1038/s41591-020-01195-4 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. 10.3322/caac.21590 - DOI - PubMed